Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Samir Kapadia, MD, is the Section Head of Invasive/Interventional Cardiology, the Director of the Sones Cardiac Catheterization Laboratories and Director of the Interventional Cardiology Fellowship Program in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine. He is a Professor of Medicine at the Lerner College of Medicine, Case Western Reserve University. He is board-certified in internal medicine, cardiology and interventional cardiology. As an interventional cardiologist, Dr. Kapadia has a special interest in complex coronary, structural heart disease-related cardiac interventions as well as carotid and peripheral interventions.
A native of India, Dr. Kapadia received his medical degree with honors from Smt. N.H.L.M. Medical College in Gujarat, India, and scoring sixth highest out of 30,000 pre-med students on the state boards. He completed his internship and residency in internal medicine at Baylor College of Medicine in Houston, where he was named Outstanding Resident. He came to Cleveland Clinic for a fellowship in cardiology and stayed on for a fellowship in interventional cardiology, and during this time he became Chief Interventional Fellow. Dr. Kapadia was appointed to Cleveland Clinic in 2003 as a staff interventional cardiologist.
Prior to his appointment to Cleveland Clinic, Dr. Kapadia had an academic appointment to the Department of Medicine at the University of Washington, and he served as an interventional cardiologist at the Puget Sound Health Care System of the Veterans Administration Hospital in Seattle.
Dr. Kapadia has been involved as principal investigator or co-investigator in numerous clinical trials related to percutaneous replacement of aortic valve, percutaneous mitral valve repair, carotid stenting, PFO closure, to name a few. He has invented several medical devices and holds multiple US patents. He has been invited to present results of his research at national and international symposia and conferences.
He is author or co-author of more than 50 book chapters in medical textbooks on his specialty interests, and he has authored numerous articles and abstracts in medical journals on his clinical experience. Dr. Kapadia is a reviewer for the peer-reviewed medical journals like Circulation, Journal of the American College of Cardiology, Nature, American Journal of Cardiology and the Journal of the American Medical Association. He grades abstracts for the American College of Cardiology. American Heart Association and SCAI. Dr. Kapadia is Fellow of the American College of Cardiology, Society of Vascular Medicine, and a Member of the American Heart Association.
Since 2004, Cleveland Magazine named Dr. Kapadia to its list of "Top Doctors."
coronary interventions, percutaneous treatment of valvular heart disease, ASD/PFO closure, carotid interventions, peripheral interventions.
Innovations & Patents
Devices for Percutaneous Valve Treatments
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 6/10/2015, Dr. Kapadia has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.